121032-29-9 Nelarabine AKSci R077
 
 
Loading Please Wait...
  R077    AKSci Bioscience Reagent
Nelarabine
, 95%
 
Arranon, 9-β-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
506u
GW 506U78
more..




IDENTITY
CAS Number:121032-29-9
MDL Number:MFCD00871078
MF:C11H15N5O5
MW:297.27
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:127-130°C
Optical Rotation:+55.9° (c=0.27, DMF)
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Application(s):DNA synthesis and cytotoxicity inhibitor
Form:Free Base

REVIEW

 A chemotherapy drug used in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

REFERENCES
[1]Sigalas, P. et al.: Leuk. Res., 33, e61 (2009)
[2] Cohen, M.H. et al.: Oncologist, 13, 709 (2008)
[3] Hernandez-Ilizaliturri, F.J. et al.: Clin. Med. Therap., 1, 505 (2009)

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 16, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Chemotherapeutics


PubChem